Lenalidomide-related diarrhea is associated with gut microbiota dysbiosis and disruption of the bile acid pool
Abstract
Abstract Background Lenalidomide is a cornerstone of multiple myeloma (MM) treatment, but frequently causes gastrointestinal (GI) toxicity, which often manifests as diarrhea. Lenalidomide-related diarrhea (LRD) affects quality-of-life and therapeutic tolerance. A case series of 12 patients suggested bile acid (BA) malabsorption is present in LRD (PMID: 25301337). Symptom responsiveness to BA binders (colesevelam) has been described (PMID: 39300066), but the underlying mechanism of LRD is not known. Because microbial metabolism of BAs is integral to GI homeostasis, disruption of the gut microbiota and BA pool can exacerbate many GI diseases. We hypothesized gut microbiota disruption affects BA processing capacity and contributes to LRD. Methods Two prospective trials evaluating single-agent lenalidomide maintenance after front-line MM therapy were performed at our institution (NCT02538198, NCT04497961). Stool and PRO-CTCAE questionaries were collected pre-treatment (baseline) and on lenalidomide (on-len) at regular intervals. Patients submitted additional stool and PRO-CTCAE at diarrhea onset. Dietary food frequency questionaries were also collected. On-len stool samples were overlayed with PRO-CTCAE diarrhea responses and classified as on-len control (Never, Rarely) or on-len diarrhea (Occasionally, Frequently, Almost Constantly). Patients reporting diarrhea at baseline were excluded. 16S rRNA sequencing was performed on stool samples. Alpha-diversity (Simpson's reciprocal index) was modelled with a multivariable generalized estimating equation (GEE). Between-group microbial differences (beta-diversity) were defined by Bray-Curtis distance and assessed with PERMANOVA. FLORAL GEE models were used to select predictive microbial taxa. Stool BAs were quantified by LC-MS/MS and compared using linear mixed-effects models with Tukey-adjusted pairwise comparisons. PICRUSt2 was used to predict metagenomic functions. Dietary nutrient densities were compared with Wilcoxon rank-sum tests, reported as raw p-values and Benjamini-Hochberg adjusted q-values. Analyses used R and Python. Results 72 patients with MM were included. 40/72 (56%) previously underwent autologous hematopoietic cell transplantation (AHCT). 129 stool samples from 72 patients were profiled and classified as follows: baseline (N=54), on-len control (N=58), and on-len diarrhea (N=17). A GEE model (adjusted for AHCT, sex, and antibiotic exposure) revealed significantly lower alpha-diversity in on-len diarrhea samples compared to both baseline (p<0.001) and on-len control (p=0.004). Beta-diversity was significantly shifted in the on-len diarrhea group from both the baseline and on-len control groups (F=3.9, p=0.001). In a FLORAL GEE model comparing baseline and on-len diarrhea groups, Faecalibacterium and Romboutsia genera were depleted in the on-len diarrhea group. Metabolomic profiling of BAs was performed in 103/129 samples. Primary BAs, which promote BA diarrhea, were significantly enriched in on-len diarrhea samples compared to baseline, including cholate (p=0.002) and chenodeoxycholate (p=0.010). Primary BAs are metabolized into secondary BAs by microbial enzymes; secondary BA levels were similar between baseline, on-len control and on-len diarrhea groups, including deoxycholate (overall p=0.679) and lithocholate (overall p=0.250). Despite the higher primary BA load, the predicted abundance of bile salt hydrolase (BSH), which mediates the first microbial step of BA metabolism, was significantly lower in the on-len diarrhea group compared to baseline (p=0.029) and on-len control groups (p=0.030). Predicted abundance of bai operon genes, which mediate downstream processing of secondary BAs, was similar between the three groups (overall p=0.890). Analysis of dietary macronutrient density from 39/72 patients with baseline data revealed those who developed diarrhea had a trend toward higher total fat intake (p=0.059). In an analysis of nutrient subclasses, patients who did not develop diarrhea had trends toward higher intake of soluble fiber (p=0.011; q=0.085) and insoluble fiber (p=0.067; q=0.178). Conclusion Our study provides the first evidence of gut microbiota dysbiosis in patients with LRD. We reveal primary BA enrichment in patients with LRD, which correlated with disrupted microbial processing capacity. These data suggest that beyond bile acid sequestration, strategies to improve gut microbial diversity and functional capacity may warrant further study for mitigation of LRD.
Article Details
Authors (28)
Kevin Miller
1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States
Teng Fei
College of Life and Health Sciences, Northeastern University
Ruben Ramos
2Memorial Sloan Kettering Cancer Center, New York, United States
Ana Catarina Gradissimo De Oliveira
1Memorial Sloan Kettering Cancer Center, Pediatrics, New York, United States
Jennifer Haber
1Memorial Sloan Kettering Cancer Center, Pediatrics, New York, United States
Minsu Jaun
2Memorial Sloan Kettering Cancer Center, New York, United States
Francesca Castro
1Memorial Sloan Kettering Cancer Center, Myeloma and Cellular Therapy Services, New York, United States
Andriy Derkach
Issam Hamadeh
6Memorial Sloan Kettering Cancer Center, Department of Pharmacy, New York, United States
Kylee Maclachlan
2Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
Malin Hultcrantz
1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States
Hani Hassoun
1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States
Sham Mailankody
Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York
Sridevi Rajeeve
1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States
Francesco Maura
Memorial Sloan Kettering Cancer Center, New York
Maximillian Merz
5Memorial Sloan Kettering Cancer Center, New York, United States
Hamza Hashmi
Memorial Sloan Kettering Cancer Center, New York
Ross Firestone
1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States
Eric Jurgens
1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States
Gunjan Shah
2Memorial Sloan Kettering Cancer Center, Cellular Therapy Service, Department of Medicine, New York, United States
Michael Scordo
Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York
Heather Landau
Adult Bone Marrow Transplantation Service Memorial Sloan Kettering Cancer Center New York New York USA
Jonathan Peled
1Memorial Sloan Kettering Cancer Center, Pediatrics, New York, United States
Sergio Giralt
1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
Neha Korde
1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States
Saad Usmani
8Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
Urvi Shah
1Memorial Sloan Kettering Cancer Center, Myeloma Service, Division of Hematologic Malignancies, Department of Medicine, New York, United States
Alexander Lesokhin
1Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, United States